Activity Provided By:

Purdue University College of Pharmacy

Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?

Overview / Abstract:	Though treatable, multiple myeloma (MM) remains incurable. Patients inevitably experience relapse or develop resistance to initial multidrug combinations in spite of high complete response (CR) rates. The growing number of novel agents holds increasing promise of benefit for patients who relapse and/or become refractory to therapy, but improving the prognosis for these patients requires clinicians to adjust their therapeutic strategies based on the availability of these agents. There remains a need for additional drugs in the salvage setting, as many patients relapse or become resistant even to the newest agents. The list of available agents for patients with relapsed/refractory MM grew by one in 2019, and the progress of immunotherapy may lead to further expansions of the MM armamentarium in 2020. This activity will help oncology health care providers (HCPs) keep pace with the newly approved and investigational therapies available for the care of MM patients who are refractory to or have relapsed after multiple therapies, as well as the rationale and recommended strategies for their use.
Expiration	Sep 24, 2021
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online
Credits / Hours	1.5
Accreditation	ACCME, ABIM, MOC, ACPE
Presenters / Authors / Faculty	Jesus G. Berdeja, MD—Program Chair Director of Multiple Myeloma Research Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee Joshua Richter, MD Assistant Professor of Medicine Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai Director of Myeloma: Blavatnik Family – Chelsea Medical Center at Mount Sinai New York, New York
Activity Specialities / Related Topics	Hematology, Oncology / Cancer / Radiation Therapy
Sponsors / Supporters / Grant Providers	This activity is supported by educational grants from Amgen Inc., Bristol Myers Squibb, and Oncopeptides.
Keywords / Search Terms	RedMedEd Web-based, Technology, Online, Virtual, Interactive, CME, Free, Free CE, Free CME, MMRF, RedMedEd, multiple myeloma, relapsed/refractory multiple myeloma, RRMM, hematology/oncology, oncology, hematology, immunotherapy, small molecules, unmet needs Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map